The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Year in Review: Rheumatic Disease Research in 2019

Year in Review: Rheumatic Disease Research in 2019

November 20, 2019 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ATLANTA—Encouraging data on interleukin (IL) 23/IL-17 pathway drugs in psoriatic arthritis (PsA), JAK inhibitors in rheumatoid arthritis (RA) treatment and new evidence on physical activity and bone health in women were among the highlights of the 2019 ACR/ARP Annual Meeting’s Clinical Year in Review.

You Might Also Like
  • Year in Review: The ACR Advances Education, Rheumatic Disease Awareness, Strategic Planning in 2017
  • ACR Advocacy: 2019 Year in Review
  • As Role of Kinase Inhibitors in Rheumatic Disease Treatment Expands, Experts Review Therapy’s Failures, Successes
Explore This Issue
December 2019
Also By This Author
  • Calcium Crystal Deposition in Rheumatic Diseases: Mechanisms & Evaluation of Calcium Crystal Deposits Explored

Susan Manzi, MD, MPH, director of the Lupus Center for Excellence in the Autoimmunity Institute, Allegheny Health Network, Pittsburgh, who reviewed the clinical headlines, called it “the year for psoriatic arthritis.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Early, aggressive tumor necrosis factor (TNF) therapy may be beneficial. A study of golimumab plus methotrexate (MTX) vs. MTX alone as first-line treatment of PsA found that not only was there a striking difference in DAS CRP remission over 22 weeks—81% for golimumab and 42% for the MTX-only arm—but the effects were seen early, with a significant difference after just eight weeks, Dr. Manzi noted.1

Dr. Manzi photo

Dr. Manzi

Other results unveiled over the past year show that the IL-23 inhibitor risankizumab was superior to anti-TNF adalimumab for moderate to severe plaque psoriasis, with 72% vs. 47% respectively achieving at least a 90% reduction in the Psoriasis Area and Severity Index (PASI) over 16 weeks.2 Also encouraging was a large study showing no significant difference in atrial fibrillation and cardiovascular events between ustekinumab and TNF inhibitors.3

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Manzi said data show JAK inhibitors “continue to show promise in RA,” including in patients refractory to biologic disease-modifying anti-rheumatic drugs.

Monotherapy with upadacitinib, a JAK-I inhibitor, in those with active RA and an inadequate response to methotrexate, produced significantly greater ACR20 responses than methotrexate alone over 14 weeks in a recent phase 3 trial.4

Other research has deepened clinicians’ understanding of how to prevent fractures in women. Data from the Women’s Health Initiative—with a population followed over 14 years—show that an increase in physical activity lowers the risk for total fractures and hip fractures among women. A key finding in the study, Dr. Manzi said, is that this protection was seen even in those who were sedentary for more than 9.5 hours a day.5

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“Physical activity seemed to mitigate the risk of fractures seen with sedentary behavior,” she said. Mild physical activity, including golf and walking, lowered the fracture risk—an aspect of the study that “may change guidelines,” she said. “This is important since we can encourage light physical activity in our elderly patients who may be frail.”

In other corners of rheumatology, the U.S. Food and Drug Administration (FDA) approved the tyrosine kinase-inhibitor nintedanib for systemic sclerosis interstitial lung disease and the PDE4 inhibitor apremilast for oral ulcers associated with Behçet’s disease.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Osteoarthritis Tagged With: 2019 ACR/ARP Annual Meeting, Fractures, JAK inhibitors, Knee Osteoarthritis (OA), physical activity, Psoriatic Arthritis, ResearchIssue: December 2019

You Might Also Like:
  • Year in Review: The ACR Advances Education, Rheumatic Disease Awareness, Strategic Planning in 2017
  • ACR Advocacy: 2019 Year in Review
  • As Role of Kinase Inhibitors in Rheumatic Disease Treatment Expands, Experts Review Therapy’s Failures, Successes
  • Research Provides Insight into Impact of Microbiome on Health, Rheumatic Disease

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.